Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Extrapyramidal Side Effects of Antipsychotic Treatment: Scope of Problem and Impact on Outcome

Extrapyramidal Side Effects of Antipsychotic Treatment: Scope of Problem and Impact on Outcome clinicians worked with antipsychotic drugs (conventional or typical) that almost invariably caused extrapyramidal symptoms (EPS) at clinically effective doses. This led to the false impression that all antipsychotics were the same, and that EPS were an unavoidable consequence of effective antipsychotic therapy. EPS adversely impact several aspects of antipsychotic efficacy and tolerability, thereby worsening outcome of afflicted individuals. EPS reduce beneficial effects of antipsychotic treatment on the negative, cognitive, and mood symptom domains, while increasing the risk of tardive dyskinesia and reducing compliance. By definition, the newer generation of “atypical” antipsychotic agents are significantly better than conventional agents with regard to EPS (i.e., they are clinically effective at doses at which they do not cause EPS). Pharmacologically, this difference is expressed in the greater degree of separation between respective dose response curves for antipsychotic and EPS effects observed for “atypical” in contrast to conventional agents. Clinically, this EPS advantage of atypical antipsychotics translates into several important benefits, including better negative symptom efficacy, less dysphoria, less impaired cognition, a lower risk of TD, and better overall outcome. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Extrapyramidal Side Effects of Antipsychotic Treatment: Scope of Problem and Impact on Outcome

Tandon, Rajiv; Jibson, Michael
Annals of Clinical Psychiatry , Volume 14 (2) – Oct 10, 2004
Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/extrapyramidal-side-effects-of-antipsychotic-treatment-scope-of-X30LwjBDe3
Publisher
Springer Journals
Copyright
Copyright © 2002 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1016811222688
Publisher site
See Article on Publisher Site

Abstract

clinicians worked with antipsychotic drugs (conventional or typical) that almost invariably caused extrapyramidal symptoms (EPS) at clinically effective doses. This led to the false impression that all antipsychotics were the same, and that EPS were an unavoidable consequence of effective antipsychotic therapy. EPS adversely impact several aspects of antipsychotic efficacy and tolerability, thereby worsening outcome of afflicted individuals. EPS reduce beneficial effects of antipsychotic treatment on the negative, cognitive, and mood symptom domains, while increasing the risk of tardive dyskinesia and reducing compliance. By definition, the newer generation of “atypical” antipsychotic agents are significantly better than conventional agents with regard to EPS (i.e., they are clinically effective at doses at which they do not cause EPS). Pharmacologically, this difference is expressed in the greater degree of separation between respective dose response curves for antipsychotic and EPS effects observed for “atypical” in contrast to conventional agents. Clinically, this EPS advantage of atypical antipsychotics translates into several important benefits, including better negative symptom efficacy, less dysphoria, less impaired cognition, a lower risk of TD, and better overall outcome.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 10, 2004

References

  • Current Psychotherapeutic Drugs
    Tandon, R
  • Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
    Kane, JM; Honigfeld, G; Singer, J; Meltzer, H
  • Risperidone in the treatment of schizophrenia
    Marder, SR; Meibach, RC
  • Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial
    Beasley, CM; Hamilton, SH; Crawford, AM; Tollefson, G
  • Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group
    Arvanitis, LA; Miller, BG
  • Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Ziprasidone Study Group
    Daniel, DG; Zimbroff, DL; Potkin, SG; Reeves, KR; Harrigan, EP; Lakshminarayanan, M
  • Motor and mental aspects of EPS
    Casey, DE
  • The many faces of akathisia
    Van Putten, T
  • Suicide attempts associated with akathisia
    Drake, RE; Ehrlich, J
  • Response to antipsychotic medication: The doctor's and the consumer's view
    Van Putten, T; May, PR; Marder, SR
  • Compliance and outcome in patients treated with antipsychotics: The impact of extrapyramidal syndromes
    Hummer, M; Fleischhacker, WW
  • Neuroleptic withdrawal in schizophrenic patients. A review of the literature
    Gilbert, PL; Harris, MJ; McAdams, LA; Jeste, DV
  • Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?
    DeQuardo, J. T. R.
  • Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia
    Miller, DD; Tandon, R
  • Contemporary Issues in the Treatment of Schizophrenia
    Tandon, R; Jibson, MD; Taylor, SF; DeQuardo, JR
  • Covariance of positive and negative symptoms during clozapine treatment in schizophrenia
    Tandon, R; Goldman, RS; DeQuardo, JR; Perez, M; Goodson, J; Jibson, MD
  • Apath-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study
    Moller, HJ; Muller, H; Borison, RL; Schooler, NR; Chouinard, G
  • Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
    Tollefson, GD; Sanger, TM; Lu, Y; Thieme, ME
  • Antipsychotics from theory to practice: Integrating clinical and basic data
    Tandon, R; Milner, K; Jibson, MD
  • Neurocognitive impairment in schizophrenia and howit affects treatment options
    Bilder, RM
  • Cholinergic aspects of schizophrenia
    Tandon, R
  • The effects of neuroleptics on neuropsychological test results of schizophrenics
    Medalia, A; Gold, J; Merriam, A
  • Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia
    Spohn, HE; Strauss, ME
  • Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients
    Tune, LE; Strauss, ME; Lew, MF; Breitlinger, E; Coyle, JT
  • Effects of anticholinergic medication on memory in schizophrenia
    Strauss, ME; Reynolds, KS; Jayaram, G; Tune, LE
  • Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment
    Harvey, PD; Keefe, RSE
  • Effects of clozapine on cognitive function in schizophrenia
    Lee, MA; Thompson, PA; Meltzer, HY
  • The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
    Meltzer, HY; McGurk, SR
  • Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment
    Harvey, PD; Keefe, RSE
  • Depression in patients with schizophrenia during an acute psychotic episode
    Tapp, A; Kilzieh, N; Wood, AE; Raskind, M; Tandon, R
  • Depression in schizophrenia. Perspective in the era of "atypical" antipsychotic agents
    Siris, SG
  • The prevalence of comorbid substance misuse and its influence on suicidal ideation among in-patients with schizophrenia
    Kamali, M; Kelly, L; Gervin, M
  • The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia
    Atbasoglu, EC; Schultz, SK; Andreasen, NC
  • Tardive dyskinesia: Prevalence, incidence, and risk factors
    Kane, JM; Woerner, M; Lieberman, J
  • Clinical relationship of extrapyramidal symptoms and tardive dyskinesia
    Andrew, HG
  • Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients
    Chatterjee, A; Chakos, M; Koreen, A; Geisler, G; Sheitmon, B; Woerner, M; Kane, JM; Alvir, J; Lieberman, JA
  • New atypical antipsychotic medications
    Jibson, MD; Tandon, R
  • Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia?
    Casey, DE
  • Prediction of Neuroleptic Treatment Outcome in Schizophrenia
    Naber, D; Walther, A; Kirshere, T
  • Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profiles, and impact on quality of life
    Voruganti, L; Cortese, L; Oyewumi, L; Awad, G
  • Possible predictors of neuroleptic-resistant schizophrenic relapse: Influence of negative symptoms and acute extrapyramidal side effects
    Kinon, BJ; Kane, JM; Chakos, M; Munne, R
  • The new generation of antipsychotics: How atypical are they?
    Goldstein, JM
  • Treatment of schizophrenia
    Jibson, MD; Tandon, R